Tériparatide : interactions médicamenteuses

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (notice Brimonidine et timolol, Mises en garde et précautions)

Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). (notice Choriogonadotropine alfa, Contre-indications)

Clomiphene citrate tablets are contraindicated in patients with uncontrolled thyroid or adrenal dysfunction or in the presence of an organic intracranial lesion such as pituitary tumor (see INDICATIONS AND USAGE). (notice Clomifène, Contre-indications)

When concomitant administration of corticosteroids and levothyroxine is required, administration of corticosteroid should precede the initiation of levothyroxine therapy to avoid adrenal crisis. (notice Dexaméthasone, Mises en garde et précautions)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (notice Dorzolamide et timolol, Mises en garde et précautions)

WARNING: RISK OF THYROID C-CELL TUMORS In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. (notice Dulaglutide, Mise en garde encadrée)

Reactions including anaphylaxis have been reported [see Adverse Reactions (6.2) ] High levels of FSH indicating primary gonadal failure Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders) [see Indications and Usage (1.1 , 1.2 , 1.3) ] Hypersensitivity reactions to streptomycin or neomycin. (notice Follitropine, Contre-indications)

Do not take thyroid hormone replacement therapy within 2 hours of dosing with LANTHANUM CARBONATE. (notice Lanthane, Interactions médicamenteuses)

WARNING: RISK OF THYROID C-CELL TUMORS • Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. (notice Liraglutide, Mise en garde encadrée)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blockade which might precipitate a thyroid storm. (notice Nadolol, Mises en garde)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-blockade which might precipitate a thyroid crisis. (notice Pindolol, Mises en garde)

Avoid abrupt withdrawal of beta-blockade, which may precipitate a thyroid storm. (notice Propranolol, Mises en garde et précautions)

WARNING: RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (notice Sémaglutide, Mise en garde encadrée)

Thyroid Abnormalities Avoid abrupt withdrawal of beta-blockade which might be followed by an exacerbation of symptoms of hyperthyroidism, including thyroid storm. (notice Sotalol, Mises en garde et précautions)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (notice Timolol, Mises en garde et précautions)

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (notice Tirzépatide, Mise en garde encadrée)

People who have thyroid problems (hyperthyroidism) may have a higher chance of having a hypertensive crisis. (notice Tranylcypromine, Mise en garde encadrée)

Abrupt withdrawal of β-blockade may precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom acebutolol therapy is to be withdrawn should be monitored closely. (notice Acébutolol, Mises en garde)

Levothyroxine The bioavailability of alendronate was slightly decreased when BINOSTO and levothyroxine were co-administered to healthy subjects [see Clinical Pharmacology (12.3) ] . (notice Acide alendronique, Interactions médicamenteuses)

…[see Warnings and Precautions (5.6) and Adverse Reactions (6) ]. β-blockers, such as propranolol Cyclopropane or halogenated hydrocarbon anesthetics, such as halothane Antihistamines Thyroid hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids… (notice Adrénaline, Interactions médicamenteuses)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (notice Alogliptine et metformine, Interactions médicamenteuses)

Thyroid Abnormalities Nexterone inhibits peripheral conversion of throxine (T4) to triiodothyronine (T3) and may cause increased T3 levels, and increased levels of inactive reverse T3 (rT3) in clinically euthyroid patients. (notice Amiodarone, Mises en garde et précautions)

Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom TENORMIN therapy is to be withdrawn should be monitored closely. (notice Aténolol, Mises en garde)

Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom atenolol and chlorthalidone therapy is to be withdrawn should be monitored closely. (notice Aténolol et chlortalidone, Mises en garde)

Monitor thyroid function before initiation of, and periodically throughout, treatment with INLYTA. (notice Axitinib, Mises en garde et précautions)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

Abrupt withdrawal of beta-blockade might precipitate a thyroid storm; therefore, patients known or suspected of being thyrotoxic from whom betaxolol is to be withdrawn should be monitored closely (see Dosage and Administration: Cessation of therapy ). (notice Bétaxolol, Mises en garde)

Monitor and replace thyroid hormone if needed. (notice Bexarotène, Mises en garde et précautions)

Laboratory Test Interactions Based on reports involving thiazides, bisoprolol fumarate and hydrochlorothiazide tablets may decrease serum levels of protein-bound iodine without signs of thyroid disturbance. (notice Bisoprolol et hydrochlorothiazide, Précautions)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (notice Chlorure de calcium, Interactions médicamenteuses)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

Concomitant use with colesevelam hydrochloride may decrease the exposure of the following drugs: Drugs with a narrow therapeutic index (e.g., cyclosporine), phenytoin, thyroid hormone replacement therapy, warfarin, oral contraceptives containing ethinyl estradiol and norethindrone, olmesartan medoxomil, and sulfonylureas (glimepiride, glipizide, glyburide). (notice Colésévélam, Interactions médicamenteuses)

Drug Interactions Cholestyramine for Oral Suspension USP may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic), or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis. (notice Colestyramine, Interactions médicamenteuses)

Other metabolic events include a reduction in thyroid binding globulin and T4 with increased uptake of T3, but without disturbance of thyroid stimulating hormone or of free thyroxin index. (notice Danazol, Précautions)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

In patients with thyroid disease or those taking thyroid medication, because of the possibility of cardiovascular toxicity, including arrhythmias. e. (notice Désipramine, Mises en garde)

Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because serum concentrations of thyroid-binding globulin increases with use of COCs. (notice Désogestrel et éthinylestradiol, Interactions médicamenteuses)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

…and blood components may be affected by oral contraceptives: a) Increased prothrombin and factors VII, VIII, IX and X; decreased antithrombin III; increased platelet aggregability. b) Increased thyroid binding globulin (TBG), leading to increased circulating total thyroid hormone as measured by protein-bound iodine (PBI), T 4 by column or by radioimmunoassay. (notice Diacétate d'étynodiol et éthinylestradiol, Précautions)

Risk of Digoxin Toxicity Hypercalcemia may predispose patients to digitalis toxicity because FORTEO transiently increases serum calcium. (notice Tériparatide, Mises en garde et précautions)

Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because serum concentrations of thyroid-binding globulin increase with use of COCs [see Drug Interactions ( 7.2 )] . (notice Drospirénone et éthinylestradiol, Mises en garde et précautions)

Abnormal Thyroid Function Tests Dose-dependent decreases in serum T3 and T4 (free and total) values have been observed in patients taking APTIOM. (notice Eslicarbazépine, Mises en garde et précautions)

Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, monitor patients for signs of thyrotoxicosis when withdrawing beta blocking therapy. (notice Esmolol, Mises en garde et précautions)

Hypothyroidism Estrogen administration leads to increased thyroid-binding globulin (TBG) levels. (notice Estradiol, Précautions)

Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because serum concentrations of thyroid-binding globulin increase with use of COCs [see Clinical Pharmacology ( 12.3 )] . (notice Estradiol et diénogest, Mises en garde et précautions)

Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia or cholestatic jaundice occurs ( 5.5 , 5.6 , 5.9 , 5.10 ) Monitor thyroid function in women on thyroid replacement therapy ( 5.11 , 5.18 ) (notice Estradiol et noréthistérone, Mises en garde et précautions)

Hypothyroidism Estrogen administration leads to increased thyroid-binding globulin (TBG) levels. (notice Estrogènes conjugués, Précautions)

• Monitor thyroid function in women on thyroid replacement therapy ( 5.10 , 5.17 ) (notice Estrogènes conjugués et bazédoxifène, Mises en garde et précautions)

The dose of replacement thyroid hormones or cortisol therapy may need to be increased. (notice Étonogestrel et éthinylestradiol, Mises en garde et précautions)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

Thyroid hormones High-doses (> 80 mg) of furosemide may inhibit the binding of thyroid hormones to carrier proteins and result in transient increase in free thyroid hormones, followed by an overall decrease in total thyroid hormone levels. (notice Furosémide, Interactions médicamenteuses)

…somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid. (notice Glimépiride, Interactions médicamenteuses)

…olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs. (notice Glipizide, Interactions médicamenteuses)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

…recommended that appropriate references first be consulted to determine the usual precautions for the use of the other drug; e.g., when epinephrine is injected along with hyaluronidase, the precautions for the use of epinephrine in cardiovascular disease, thyroid disease, diabetes, digital nerve block, ischemia of the fingers and toes etc., should be observed. (notice Hyaluronidase, Interactions médicamenteuses)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

…levels of the drug; Patients with history of urinary retention, or history of narrow-angle glaucoma because of the drug's anticholinergic properties; hyperthyroid patients or those on thyroid medication because of the possibility of cardiovascular toxicity; patients with a history of seizure disorder because this drug has been shown to lower the seizure threshold;… (notice Imipramine, Mises en garde)

…Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (notice Insuline asparte, Interactions médicamenteuses)

…Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (notice Insuline dégludec, Interactions médicamenteuses)

…Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (notice Insuline détémir, Interactions médicamenteuses)

…Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (notice Insuline glargine, Interactions médicamenteuses)

…Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (notice Insuline lispro, Interactions médicamenteuses)

Thyroid function should be monitored periodically. (notice Interféron bêta-1a, Mises en garde et précautions)

Drugs that may potentiate clinical response of Isoproterenol Clinical Impact The effects of isoproterenol may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine. (notice Isoprénaline, Interactions médicamenteuses)

Thyroid Function Abnormalities : Decreases in thyroid function may occur; perform tests where clinically indicated. (notice Lanréotide, Mises en garde et précautions)

The dose of replacement thyroid hormone or cortisol therapy may need to be increased. (notice Lévonorgestrel et éthinylestradiol, Mises en garde et précautions)

• Hypothyroidism and Hyperthyroidism: Monitor thyroid function regularly ( 5.7 ). (notice Lithium, Mises en garde et précautions)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

The risk of hypertension increases with concomitant administration of drugs that increase blood pressure (phenylephrine, pseudoephedrine, ephedrine, dihydroergotamine, thyroid hormones, or droxidopa). (notice Midodrine, Interactions médicamenteuses)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

Drugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of Nateglinide and Increase Susceptibility to Hyperglycemia Drugs: Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogues (e.g., lanreotide, octreotide), and CYP inducers (e.g., rifampin, phenytoin and St John's Wort). (notice Natéglinide, Interactions médicamenteuses)

The dose of replacement thyroid hormone or cortisol therapy may need to be increased. (notice Norelgestromine et éthinylestradiol, Mises en garde et précautions)

• Thyroxine concentrations may be decreased, due to a decrease in thyroid binding globulin (TBG). (notice Noréthistérone, Précautions)

Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because serum concentrations of thyroid binding globulin increase with use of COCs. (notice Noréthistérone et éthinylestradiol, Mises en garde et précautions)

The dose of replacement thyroid hormone or cortisol therapy may need to be increased. (notice Norgestimate et éthinylestradiol, Mises en garde et précautions)

Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because serum concentration of thyroid-binding globulin increases with use of COCs. (notice Norgestrel et éthinylestradiol, Interactions médicamenteuses)

Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (notice Octréotide, Mises en garde et précautions)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

Drug Interactions and Decreased Vitamin Absorption ORLISTAT may interact with concomitant drugs including cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, and antiretroviral drugs [see Drug Interactions (7) ]. (notice Orlistat, Mises en garde et précautions)

Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. (notice Pasiréotide, Mises en garde et précautions)

Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (notice Pazopanib, Mises en garde et précautions)

…somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid. (notice Pioglitazone et glimépiride, Interactions médicamenteuses)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

Thyroid function: increase in PBI, and butanol extractable protein bound iodine and decrease in T3 uptake values. (notice Progestérone, Interactions médicamenteuses)

Ask a doctor before use if you have heart disease high blood pressure thyroid disease diabetes trouble urinating due to an enlarged prostate gland When using this product do not exceed recommended dosage Stop use and ask a doctor if nervousness, dizziness, or sleeplessness occur symptoms do not improve within 7 days or occur with a fever If pregnant or breast-feeding,… (notice Pseudoéphédrine, Mises en garde)

Hypothyroidism Adults: Clinical trials with quetiapine demonstrated dose-related decreases in thyroid hormone levels. (notice Quétiapine, Mises en garde et précautions)

Substitute non-enzyme inducing therapies at least 2 weeks prior to initiation of irinotecan therapy Decrease irinotecan and active metabolite exposure Levothyroxine Decrease exposure Losartan Parent Decrease AUC by 30% Active metabolite (E3174) Decrease AUC by 40% Methadone In patients well-stabilized on methadone, concomitant administration of rifampin resulted… (notice Rifampicine, Interactions médicamenteuses)

…levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline, nortriptyline 7.5 Other Interactions The conversion of PRIFTIN to 25-desacetyl rifapentine is mediated by an esterase enzyme. (notice Rifapentine, Interactions médicamenteuses)

For oral medication where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy (e.g., cyclosporine, tacrolimus, levothyroxine), consider separation of the timing of the administration of the two drugs [see Clinical Pharmacology (12.3) ] . (notice Sévélamer, Interactions médicamenteuses)

Hypothyroidism: Monitor thyroid function periodically as hypothyroidism may occur or worsen after initiation of somatropin. (notice Somatropine, Mises en garde et précautions)

• Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (notice Sorafénib, Mises en garde et précautions)

• Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (notice Sunitinib, Mises en garde et précautions)

Drug-Laboratory Test Interactions There are postmarketing reports of T 4 elevations in postmenopausal patients taking tamoxifen that may be explained by increases in thyroid-binding globulin. (notice Tamoxifène, Interactions médicamenteuses)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

Caution is advised in patients with history of urinary retention because of the drug's anticholinergic properties; hyperthyroid patients or those on thyroid medication because of the possibility of cardiovascular toxicity; patients with a history of seizure disorder, because this drug has been shown to lower the seizure threshold; patients receiving guanethidine… (notice Trimipramine, Mises en garde)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (notice Acarbose, Interactions médicamenteuses)

Effect on Ketone and Thyroid Function Tests Valproate is partially eliminated in the urine as a keto-metabolite which may lead to a false interpretation of the urine ketone test. (notice Acide valproïque, Mises en garde et précautions)

Hypocalcemia and Mineral Metabolism Preexisting hypocalcemia and disturbances of mineral metabolism (e.g., hypoparathyroidism, thyroid surgery, parathyroid surgery; malabsorption syndromes, excision of small intestine) must be effectively treated before initiating therapy with Reclast. (notice Acide zolédronique, Mises en garde et précautions)

Guanethidine or similarly acting compounds; thyroid medication; alcohol, barbiturates and other CNS depressants; and disulfiram – see WARNINGS section. (notice Amitriptyline, Interactions médicamenteuses)

Abrupt withdrawal of beta-blockade may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate thyroid storm. (notice Bisoprolol, Mises en garde)

Cytologic abnormalities characterized by giant, hyperchromatic nuclei have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, and bone marrow. (notice Busulfan, Mises en garde)

…dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate, glucocorticoids, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuxamide, mianserin, midazolam, mirtazapine, nefazodone, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, paliperidone, phenytoin,… (notice Carbamazépine, Interactions médicamenteuses)

Abrupt withdrawal of β-blockade may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate thyroid storm. (notice Carvédilol, Mises en garde et précautions)

Secondary malignancies (urinary tract cancer, myelodysplasia, acute leukemias, lymphomas, thyroid cancer, and sarcomas) have been reported in patients treated with cyclophosphamide-containing regimens . (notice Cyclophosphamide, Mises en garde et précautions)

Losartan, glipizide and levothyroxine did not show any changes in exposure when co-administered with LOKELMA. (notice Cyclosilicate de zirconium sodique, Interactions médicamenteuses)

Other Medications Used for the Management of Fanconi Syndrome PROCYSBI can be administered with other electrolyte and mineral replacements necessary for management of Fanconi syndrome, as well as vitamin D and thyroid hormone. (notice Cystéamine, Interactions médicamenteuses)

These medications include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Dapagliflozine et metformine, Interactions médicamenteuses)

Effect on Ketone and Thyroid Function Tests Valproate is partially eliminated in the urine as a keto-metabolite which may lead to a false interpretation of the urine ketone test. (notice Divalproate de sodium (valproate), Mises en garde et précautions)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Empagliflozine et metformine, Interactions médicamenteuses)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Glibenclamide, Interactions médicamenteuses)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (notice Glibenclamide et metformine, Interactions médicamenteuses)

These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Glipizide et metformine, Précautions)

Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (notice Gluconate de calcium, Interactions médicamenteuses)

Cases of myelodysplastic syndrome, acute leukemias, lymphomas, thyroid cancers, and sarcomas have occurred and may develop several years after chemotherapy has been discontinued. (notice Ifosfamide, Mises en garde et précautions)

Hypothyroidism has been reported in thyroidectomy patients undergoing levothyroxine replacement. (notice Imatinib, Mises en garde et précautions)

Atypical Antipsychotics (e.g., olanzapine and clozapine), Corticosteroids, Danazol, Diuretics, Estrogens, Glucagon, Isoniazid, Niacin, Oral Contraceptives, Phenothiazines, Progestogens (e.g., in oral contraceptives), Protease inhibitors, Somatropin, Sympathomimetic Agents (e.g., albuterol, epinephrine, terbutaline) and Thyroid Hormones. (notice Insuline rapide (humaine), Interactions médicamenteuses)

Warnings Potassium iodide can cause fetal harm, abnormal thyroid function, and goiter when administered to a pregnant woman. (notice Iodure de potassium, Mises en garde)

Thyroid Disorders Both hypothyroidism and hyperthyroidism have been reported [see Adverse Reactions (6.2) ] . (notice Lénalidomide, Mises en garde et précautions)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Linagliptine et metformine, Interactions médicamenteuses)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (notice Metformine, Interactions médicamenteuses)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (notice Méthyltestostérone, Précautions)

Thyrotoxicosis: Abrupt withdrawal in patients with thyrotoxicosis might precipitate a thyroid storm. (notice Métoprolol, Mises en garde et précautions)

Abrupt withdrawal in thyrotoxicosis might precipitate a thyroid storm. (notice Métoprolol et hydrochlorothiazide, Mises en garde et précautions)

EMROSI may induce hyperpigmentation in many organs, including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity (teeth, mucosa, alveolar bone), sclerae and heart valves. (notice Minocycline, Mises en garde et précautions)

In cases of cognitive dysfunction, thyroid function should be evaluated as mitotane may induce hypothyroidism. (notice Mitotane, Mises en garde et précautions)

Abrupt withdrawal of β-blockers may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate a thyroid storm. (notice Nébivolol, Mises en garde et précautions)

Great care is required if Pamelor is given to hyperthyroid patients or to those receiving thyroid medication, since cardiac arrhythmias may develop. (notice Nortriptyline, Mises en garde)

…performed, the following concomitant drugs were used in at least 10% of patients in either or both Sjogren's efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. (notice Pilocarpine, Interactions médicamenteuses)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (notice Pioglitazone et metformine, Interactions médicamenteuses)

On rare occasions, hyperthyroid patients or those receiving thyroid medication may develop arrhythmias when this drug is given. (notice Protriptyline, Mises en garde)

…antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (notice Répaglinide, Interactions médicamenteuses)

These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Saxagliptine et metformine, Interactions médicamenteuses)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (notice Sitagliptine et metformine, Interactions médicamenteuses)

Free thyroid hormone concentrations remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (notice Testostérone, Mises en garde et précautions)

Thyroid-stimulating hormone, total thyroxine, and thyrotropin-releasing hormone response are not affected. (notice Fénoprofène, Interactions médicamenteuses)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3)… (notice Montélukast, Interactions médicamenteuses)